NFKB1 and acute myeloid leukemia: By targeting the TNF-α/NF-κB pathway, prominently using NF-κB inhibitors and TNF-α antagonists, or even inhibiting their downstream targets, like IKK inhibitors, Bcl2 inhibitors or MDM2 inhibitors can serve as a potential therapeutic option in AML.